{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:19:09Z","timestamp":1758629949490,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL103965","R01HL113382","UM1HL119073","U01HL114589","R01HL124053"],"award-info":[{"award-number":["R01HL103965","R01HL113382","UM1HL119073","U01HL114589","R01HL124053"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK089507"],"award-info":[{"award-number":["P30DK089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000423"],"award-info":[{"award-number":["UL1TR000423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD003704"],"award-info":[{"award-number":["R01FD003704"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["RAMOS16A0"],"award-info":[{"award-number":["RAMOS16A0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["CFCID3237"],"award-info":[{"award-number":["CFCID3237"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201511MFE-359236-270022"],"award-info":[{"award-number":["201511MFE-359236-270022"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal College of Physicians and Surgeons","award":["RCPSC16\/DTF-08"],"award-info":[{"award-number":["RCPSC16\/DTF-08"]}]},{"name":"Grifols Pharmaceuticals"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40272-017-0256-y","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T07:18:20Z","timestamp":1501744700000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls"],"prefix":"10.1007","volume":"20","author":[{"given":"Kathleen J.","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1164\/rccm.201008-1312ED","volume":"183","author":"C Goss","year":"2011","unstructured":"Goss C. Comparative effectiveness research: what happened to incorporating costs of care? Am J Respir Crit Care Med. 2011;183:973\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"256_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.201008-1300ED","volume":"183","author":"J Krishnan","year":"2011","unstructured":"Krishnan J. Con: comparative effectiveness research. More than dollars and cents. Am J Respir Crit Care Med. 2011;183:975\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"256_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/thx.2005.043372","volume":"61","author":"C Que","year":"2006","unstructured":"Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2006;61(2):155\u20137.","journal-title":"Thorax"},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.7326\/0003-4819-151-3-200908040-00125","volume":"151","author":"H Sox","year":"2009","unstructured":"Sox H, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151:203\u20135.","journal-title":"Ann Intern Med"},{"key":"256_CR5","unstructured":"Federal Coordinating Counsel for Comparative Effectiveness Research. Report to the President and Congress. 3-8. 6-30. Department of Health and Human Services; 2009."},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1752-8062.2010.00177.x","volume":"3","author":"H Selker","year":"2009","unstructured":"Selker H, Strom BL, Ford DE, et al. White paper on CTSA consortium role in facilitating comparative effectiveness research: CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci. 2009;3:29\u201337.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"256_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1378\/chest.115.5.1321","volume":"115","author":"KL Fraser","year":"1999","unstructured":"Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. CHEST J. 1999;115(5):1321\u20138.","journal-title":"CHEST J"},{"issue":"37","key":"256_CR8","doi-asserted-by":"publisher","first-page":"37cm18","DOI":"10.1126\/scitranslmed.3001235","volume":"2","author":"C Clancy","year":"2010","unstructured":"Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Trans Med. 2010;2(37):37cm18.","journal-title":"Sci Trans Med"},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1001\/jama.2010.726","volume":"303","author":"M Lauer","year":"2010","unstructured":"Lauer M, Collins FS. Using science to improve the nation\u2019s health system: NIH\u2019s commitment to comparative effectiveness research. JAMA. 2010;303:2182\u20133.","journal-title":"JAMA"},{"issue":"8","key":"256_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1164\/rccm.201407-1382OC","volume":"190","author":"D Hayes Jr","year":"2014","unstructured":"Hayes D Jr, Tobias JD, Mansour HM, Kirkby S, McCoy KS, Daniels CJ, Whitson BA. Pulmonary hypertension in cystic fibrosis with advanced lung disease. Am J Resp Crit Care Med. 2014;190(8):898\u2013905.","journal-title":"Am J Resp Crit Care Med"},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","volume":"333","author":"P Brown","year":"2006","unstructured":"Brown P, Bruunhuber K, Chalkidou K, et al. How to formulate research recommendations. BMJ. 2006;333:804\u20136.","journal-title":"BMJ"},{"key":"256_CR12","unstructured":"Centre for Evidence-Based Medicine \n                    http:\/\/www.cebm.net\/\n                    \n                  . Accessed 15 July 2017."},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1503\/cmaj.090523","volume":"180","author":"K Thorpe","year":"2009","unstructured":"Thorpe K, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 2009;180:E47\u201357.","journal-title":"CMAJ"},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1001\/jama.2010.807","volume":"303","author":"J Krishnan","year":"2010","unstructured":"Krishnan J, Mularski RA. Acting on comparative effectiveness research in COPD. JAMA. 2010;303:2409\u201310.","journal-title":"JAMA"},{"key":"256_CR15","first-page":"2005","volume":"305","author":"B Djulbegovic","year":"2011","unstructured":"Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. JAMA. 2011;305:2005\u20136.","journal-title":"JAMA"},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"S Tunis","year":"2003","unstructured":"Tunis S, Styer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624\u201332.","journal-title":"JAMA"},{"key":"256_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7326\/0003-4819-130-6-199903160-00005","volume":"130","author":"K Malmstrom","year":"1999","unstructured":"Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast\/Beclomethasone Study Group. Ann Intern Med. 1999;130:487\u201395.","journal-title":"Ann Intern Med"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1010846","volume":"364","author":"D Price","year":"2011","unstructured":"Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011;364:1695\u2013707.","journal-title":"N Engl J Med"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMe1100937","volume":"364","author":"S Dahlen","year":"2011","unstructured":"Dahlen S, Dahlen B, Drazen JM. Asthma treatment guidelines meet the real world. N Engl J Med. 2011;364:1769\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"256_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1164\/rccm.200502-273OC","volume":"173","author":"CH Goss","year":"2006","unstructured":"Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML. Clinical trial participants compared with nonparticipants in cystic fibrosis. Am J Respir Crit Care Med. 2006;173(1):98\u2013104.","journal-title":"Am J Respir Crit Care Med"},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","volume":"30","author":"M Treggiari","year":"2009","unstructured":"Treggiari M, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials. 2009;30:256\u20138.","journal-title":"Contemp Clin Trials"},{"key":"256_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","volume":"165","author":"M Treggiari","year":"2011","unstructured":"Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165:847\u201356.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7","key":"256_CR23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, Elbert A, Petren KM, Marshall BC. The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016;13(7):1173\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"256_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ppul.21521","volume":"47","author":"GS Sawicki","year":"2012","unstructured":"Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012;47(1):44\u201352.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"256_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/thoraxjnl-2014-205718","volume":"70","author":"CH Goss","year":"2015","unstructured":"Goss CH, MacNeill SJ, Quinton HB, Marshall BC, Elbert A, Knapp EA, Petren K, Gunn E, Osmond J, Bilton D. Children and young adults with CF in the USA have better lung function compared with the UK. Thorax. 2015;70(3):229\u201336.","journal-title":"Thorax"},{"issue":"8","key":"256_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7326\/M16-0858","volume":"166","author":"AL Stephenson","year":"2017","unstructured":"Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, Ostrenga J, Fink AK, Elbert A, Goss CH. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017;166(8):537\u201346.","journal-title":"Ann Intern Med"},{"issue":"1","key":"256_CR27","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1542\/peds.2015-0673","volume":"136","author":"AG Fiks","year":"2015","unstructured":"Fiks AG, Grundmeier RW, Steffes J, Adams WG, Kaelber DC, Pace WD, Wasserman RC. Comparative effectiveness research through collaborative electronic reporting C. comparative effectiveness research through a collaborative electronic reporting consortium. Pediatrics. 2015;136(1):e215\u201324.","journal-title":"Pediatrics"},{"issue":"6","key":"256_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCOUTCOMES.116.003308","volume":"9","author":"RC Deo","year":"2016","unstructured":"Deo RC, Nallamothu BK. Learning about machine learning: the promise and pitfalls of big data and the electronic health record. Circ Cardiovasc Qual Outcomes. 2016;9(6):618\u201320.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"256_CR29","doi-asserted-by":"publisher","unstructured":"Bel EH, ten Brinke A. New Anti-Eosinophil Drugs for asthma and COPD: targeting the trait! Chest Epub 2 June 2017. doi:\n                    10.1016\/J.CHEST.2017.05.019\n                    \n                  .","DOI":"10.1016\/J.CHEST.2017.05.019"},{"issue":"5","key":"256_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1056\/NEJM199302043280503","volume":"328","author":"E Hentschel","year":"1993","unstructured":"Hentschel E, Brandstatter G, Dragosics B, Hirschl AM, Nemec H, Schutze K, Taufer M, Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328(5):308\u201312.","journal-title":"N Engl J Med"},{"issue":"15","key":"256_CR31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199104113241507","volume":"324","author":"WL Peterson","year":"1991","unstructured":"Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991;324(15):1043\u20138.","journal-title":"N Engl J Med"},{"issue":"27","key":"256_CR32","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1002\/sim.4053","volume":"29","author":"S Everson-Stewart","year":"2010","unstructured":"Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29(27):2769\u201380.","journal-title":"Stat Med"},{"issue":"1","key":"256_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/19466315.2014.1002627","volume":"7","author":"K Odem-Davis","year":"2015","unstructured":"Odem-Davis K, Fleming TR. A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res. 2015;7(1):12\u201324.","journal-title":"Stat Biopharm Res"},{"key":"256_CR34","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1377\/hlthaff.2010.0660","volume":"29","author":"A Wu","year":"2010","unstructured":"Wu A, Snyder C, Clancy CM, Steinwachs DM. Adding the patient perspective to comparative effectiveness research. Health Aff. 2010;29:1863\u201371.","journal-title":"Health Aff"},{"key":"256_CR35","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302:1437\u201343.","journal-title":"JAMA"},{"issue":"1","key":"256_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcf.2011.08.007","volume":"11","author":"R Buzzetti","year":"2012","unstructured":"Buzzetti R, Alicandro G, Minicucci L, Notarnicola S, Furnari ML, Giordano G, Lucidi V, Montemitro E, Raia V, Magazz\u00f9 G. Validation of a predictive survival model in Italian patients with cystic fibrosis. J Cyst Fibros. 2012;11(1):24\u20139.","journal-title":"J Cyst Fibros"},{"issue":"29","key":"256_CR37","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1377\/hlthaff.2010.0647","volume":"2010","author":"A Garber","year":"2010","unstructured":"Garber A, Sox HCAM, Sox HC. The role of costs in comparative effectiveness research. Health Aff. 2010;2010(29):1805\u201311.","journal-title":"Health Aff"},{"issue":"19","key":"256_CR38","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMp0901355","volume":"360","author":"AM Garber","year":"2009","unstructured":"Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med. 2009;360(19):1925\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"256_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2165\/11535830-000000000-00000","volume":"28","author":"RS Epstein","year":"2010","unstructured":"Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics. 2010;28(10):905\u201313.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"256_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s13167-010-0058-6","volume":"1","author":"PM Brown","year":"2010","unstructured":"Brown PM. Personalized medicine and comparative effectiveness research in an era of fixed budgets. EPMA J. 2010;1(4):633\u201340.","journal-title":"EPMA J"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-017-0256-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0256-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0256-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:14:31Z","timestamp":1589670871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-017-0256-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s40272-017-0256-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2017,8,3]]},"assertion":[{"value":"3 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding support was received for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KJR receives funding from the Cystic Fibrosis Foundation (RAMOS16A0). RS receives funding from Cystic Fibrosis Canada (CFCID3237), the Canadian Institutes for Health Research (201511MFE-359236-270022), and the Royal College of Physicians and Surgeons (RCPSC16\/DTF-08). DPN receives funding from the Cystic Fibrosis Foundation and the National Institutes of Health and from NIH\/National Heart, Lung, and Blood Institute (NHLBI) (R01HL124053), Cystic Fibrosis Foundation Therapeutics, Cystic Fibrosis Foundation, Grifols Pharmaceuticals, and Gilead Sciences. He has also received grant funding from Gilead Sciences and Grifols Pharmaceutics to conduct clinical and translational research, none of which is related to the topics discussed in this review. CHG has received financial support from Gilead Sciences for grant reviews and from Boehringer Ingelheim for clinical trial design consulting. CHG also receives honoraria to serve as the Chair of a Data Safety Monitoring Board for a clinical trial jointly supported by the European Commission and Novartis. CHG was also part of a research group that received a clinical research grant from Vertex Pharmaceuticals. None of this funding is related to the topics within this review. CHG receives funding from the Cystic Fibrosis Foundation, the National Institutes of Health (NIH) (R01HL103965, R01HL113382, R01AI101307, UM1HL119073, P30DK089507, UL1TR000423 U01HL114589) and the FDA (R01FD003704).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}